| 臺大學術典藏 |
2021-03-12T02:29:06Z |
Tracheal botryomycosis in a patient with tracheopathia osteochondroplastica
|
Shih J.-Y.;Hsueh P.-R.;Chang Y.-L.;Li-Na Lee;Chen Y.-C.;Chen M.-F.;Luh K.-T.; Shih J.-Y.; Hsueh P.-R.; Chang Y.-L.; LI-NA LEE; Chen Y.-C.; Chen M.-F.; Luh K.-T. |
| 臺大學術典藏 |
2021-03-12T02:29:00Z |
Tuberculous myositis: A rare but existing clinical entity
|
Wang J.Y.;Li-Na Lee;Hsueh P.R.;Shih J.Y.;Chang Y.L.;Yang P.C.;Luh K.T.; Wang J.Y.; LI-NA LEE; Hsueh P.R.; Shih J.Y.; Chang Y.L.; Yang P.C.; Luh K.T. |
| 臺大學術典藏 |
2021-03-12T02:28:41Z |
Coinfection with Mycobacterium tuberculosis and pandemic H1N1 influenza A virus in a patient with lung cancer
|
Tan C.-K.;Kao C.-L.;Shih J.-Y.;Li-Na Lee;Hung C.-C.;Lai C.-C.;Huang Y.-T.;Hsueh P.-R.; Tan C.-K.; Kao C.-L.; Shih J.-Y.; LI-NA LEE; Hung C.-C.; Lai C.-C.; Huang Y.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-03-12T00:50:59Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H.;Yang C.-Y.;Ho C.-C.;Liao W.-Y.;I-Shiow Jan;Chen K.-Y.;Wang J.-Y.;Ruan S.-Y.;Yu C.-J.;Yang J.C.H.;Yang P.-C.;Shih J.-Y.; Tsai T.-H.; Yang C.-Y.; Ho C.-C.; Liao W.-Y.; I-SHIOW JAN; Chen K.-Y.; Wang J.-Y.; Ruan S.-Y.; Yu C.-J.; Yang J.C.H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-12T00:50:59Z |
Survival of lung adenocarcinoma patients with malignant pleural effusion
|
Wu S.-G.;Yu C.-J.;Tsai M.-F.;Liao W.-Y.;Yang C.-H.;I-Shiow Jan;Yang P.-C.;Shih J.-Y.; Wu S.-G.; Yu C.-J.; Tsai M.-F.; Liao W.-Y.; Yang C.-H.; I-SHIOW JAN; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-12T00:50:57Z |
BMVC test, an improved fluorescence assay for detection of malignant pleural effusions
|
Lin I.-T.; Tsai Y.-L.; Kang C.-C.; Huang W.-C.; Wang C.-L.; Lin M.-Y.; Lou P.-J.; Shih J.-Y.; Wang H.-C.; Wu H.-D.; Tsai T.-H.; I-SHIOW JAN; Chang T.-C. |
| 臺大學術典藏 |
2021-03-11T12:03:49Z |
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
|
Yu K.-L.;Tsai T.-H.;Ho C.-C.;Liao W.-Y.;Ching-Kai Lin;Hsu C.-L.;Shih J.-Y.; Yu K.-L.; Tsai T.-H.; Ho C.-C.; Liao W.-Y.; CHING-KAI LIN; Hsu C.-L.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:21Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:34:19Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.;Lee M.-R.;Liao W.-Y.;Ho C.-C.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:18Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.;Jen-Chang Ko;Yang J.C.-H.;Shih J.-Y.; SHENG-KAI LIANG; JEN-CHANG KO; James Chih-Hsin Yang; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:34:15Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:34:15Z |
Effect of β-Blocker in Treatment-Naive Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.;Lee C.-H.;Jen-Chang Ko;Chang L.-Y.;Lee M.-C.;Zhang J.-F.;Wang J.-Y.;Shih J.-Y.;Yu C.-J.; CHIA-HAO CHANG; Lee C.-H.; JEN-CHANG KO; LIH-YU CHANG; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:34Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:32Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:30Z |
Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:29:29Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T07:58:31Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:28Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:27Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:25Z |
Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T07:58:24Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-08T06:51:51Z |
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression
|
Lin C.-C.; Huang Y.-K.; Cho C.-F.; Lin Y.-S.; Lo C.-C.; Kuo T.-T.; Tseng G.-C.; Cheng W.-C.; Chang W.-C.; Hsiao T.-H.; Liang-Chuan Lai; Shih J.-Y.; Liu Y.-H.; Clifford Chao K.S.; Hsu J.L.; Lee P.-C.; Sun X.; Hung M.-C.; Sher Y.-P. |
| 臺大學術典藏 |
2021-02-23T08:26:39Z |
Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response
|
Gow C.-H.;Chien C.-R.;Chang Y.-L.;Chiu Y.-H.;Sung-Hsin Kuo;Shih J.-Y.;Chang Y.-C.;Yu C.-J.;Yang C.-H.;Yang P.-C.; Gow C.-H.; Chien C.-R.; Chang Y.-L.; Chiu Y.-H.; SUNG-HSIN KUO; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Yang C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2021-02-23T08:26:37Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; SUNG-HSIN KUO; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:23Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y.;Yang J.C.-H.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Lin Z.-Z.;Lan K.-H.;Cheng A.-L.;Sung-Hsin Kuo; Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Lin Z.-Z.; Lan K.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-23T08:26:16Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Sung-Hsin Kuo;Cheng J.C.-H.;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; SUNG-HSIN KUO; Cheng J.C.-H.; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2021-02-23T08:26:10Z |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Sung-Hsin Kuo; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-05T07:26:17Z |
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations
|
Kuei-Pin Chung;Shih J.-Y.;Yu C.-J.; KUEI-PIN CHUNG; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-02-05T07:26:16Z |
Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment
|
KUEI-PIN CHUNG; Huang Y.-T.; Chang Y.-L.; Yu C.-J.; Yang C.-H.; Chang Y.-C.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-02-05T07:26:14Z |
Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR
|
KUEI-PIN CHUNG; Wu S.-G.; Wu J.-Y.; Yang J.-H.; Yu C.-J.; Wei P.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-02-05T07:26:10Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Keng L.-T.;Kuei-Pin Chung;Lin S.-Y.;Liang S.-K.;Cheng J.-C.;Chen I.-C.;Chen Y.-F.;Chang H.-T.;Hsu C.-L.;Jerng J.-S.;Wang H.-C.;Kuo P.-H.;Wu H.-D.;Shih J.-Y.;Yu C.-J.; Keng L.-T.; KUEI-PIN CHUNG; Lin S.-Y.; Liang S.-K.; Cheng J.-C.; Chen I.-C.; Chen Y.-F.; Chang H.-T.; Hsu C.-L.; Jerng J.-S.; Wang H.-C.; Kuo P.-H.; Wu H.-D.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-02-05T07:26:09Z |
Multi-kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin-related protein 1
|
Kuei-Pin Chung;Huang Y.-L.;Chen Y.-J.;Juan Y.-H.;Hsu C.-L.;Nakahira K.;Huang Y.-T.;Lin M.-W.;Wu S.-G.;Shih J.-Y.;Chang Y.-L.;Yu C.-J.; KUEI-PIN CHUNG; Huang Y.-L.; Chen Y.-J.; Juan Y.-H.; Hsu C.-L.; Nakahira K.; Huang Y.-T.; Lin M.-W.; Wu S.-G.; Shih J.-Y.; Chang Y.-L.; Yu C.-J. |
| 臺大學術典藏 |
2021-01-28T01:06:43Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang C.-L.; Yang C.-H.; KUN-HUEI YEH; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Yang P.-C. |
| 臺大學術典藏 |
2021-01-27T01:38:20Z |
Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes
|
Sher Y.-P.;Shih J.-Y.;Yang P.-C.;Roffler S.R.;Chu Y.-W.;Wu C.-W.;Chia-Li Yu;Peck K.; Sher Y.-P.; Shih J.-Y.; Yang P.-C.; Roffler S.R.; Chu Y.-W.; Wu C.-W.; CHIA-LI YU; Peck K. |
| 臺大學術典藏 |
2021-01-12T03:00:19Z |
The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer
|
Ho C.-C.; Liao W.-Y.; Lin C.-K.; Hsu C.-L.; Shih J.-Y.; KAI-LUN YU; Tsai T.-H. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Shih J.-Y.; Ko J.-C.; Ho C.-C.; Liao W.-Y.; Lee M.-R.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Wang H.-C.; Hsu C.-L.; Jerng J.-S.; Chen Y.-F.; Chang H.-T.; Chen I.-C.; Cheng J.-C.; SHENG-KAI LIANG; Lin S.-Y.; Keng L.-T.; Chung K.-P.; Kuo P.-H.; Wu H.-D.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Shih J.-Y.; Ko J.-C.; Lee M.-R.; Keng L.-T.; Hsieh M.-S.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T03:40:19Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T02:56:48Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Li-Ta Keng;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T02:56:46Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Yen-Fu Chen; I-Chun Chen; Jui-Chen Cheng; SHENG-KAI LIANG; Shu-Yung Lin; Li-Ta Keng;Chung K.-P.;Lin S.-Y.;Liang S.-K.;Cheng J.-C.;Chen I.-C.;Chen Y.-F.;Chang H.-T.;Hsu C.-L.;Jerng J.-S.;Wang H.-C.;Kuo P.-H.;Wu H.-D.;Shih J.-Y.;Yu C.-J.; LI-TA KENG; Kuei-Pin Chung; Hou-Tai Chang; Chia-Lin Hsu; Jih-Shuin Jerng; Hao-Chien Wang; Ping-Hung Kuo; Huey-Dong Wu; Jin-Yuan Shih; Chong-Jen Yu |
| 國立成功大學 |
2021 |
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing
|
Lin, Y.-T.;Chiang, Chiang C.-L.;Hung, J.-Y.;Lee, M.-H.;Su, W.-C.;Wu, S.-Y.;Wei, Y.-F.;Lee, K.-Y.;Tseng, Y.-H.;Su, J.;Chung, H.-P.;Lin, C.-B.;Ku, W.-H.;Chiang, T.-S.;Chiu, Chiu C.-H.;Shih, J.-Y. |
| 國立成功大學 |
2021 |
Effects of renal impairment on cardiac remodeling and clinical outcomes after myocardial infarction
|
Chiang, Chiang C.-Y.;Huang, S.-C.;Chen, M.;Shih, J.-Y.;Hong, C.-S.;Wu, N.-C.;Ho, C.-H.;Wu, C.C.;Chen, Z.-C.;Chang, W.-T. |
| 國立成功大學 |
2021 |
The predictive value of global longitudinal strain in patients with heart failure mid-range ejection fraction
|
Chang, W.-T.;Lin, C.H.;Hong, C.-S.;Liao, C.-T.;Liu, Y.-W.;Chen, Z.-C.;Shih, J.-Y. |
| 國立成功大學 |
2021 |
Dapagliflozin improves cardiac hemodynamics and mitigates arrhythmogenesis in mitral regurgitation-induced myocardial dysfunction
|
Lin, Y.-W.;Chen, Chen C.-Y.;Shih, J.-Y.;Cheng, B.-C.;Chang, Chang C.-P.;Lin, M.-T.;Ho, C.-H.;Chen, Z.-C.;Fisch, S.;Chang, W.-T. |
| 臺大學術典藏 |
2020-12-28T12:03:34Z |
In-hospital implementation of evidence-based, medications is associated with improved survival, in diabetic patients with acute coronary, syndrome - Data from TSOC ACS-DM registry
|
Shyu K.-G.; Lin J.-F.; Lei M.-H.; Chiang C.-E.; Chang K.-C.; HWANG, JUEY-JEN; Voon W.-C.; Hsieh I.-C.; Chong J.-T.; Lin W.-S.; Hsu C.-N.; Ueng K.-C.; Hsia C.-P.; Liu J.-C.; Yeh J.-S.; Mar G.-Y.; Shih J.-Y.; Kuo J.-Y.; Tsao H.-M.; Tseng W.-K.; Yang C.-H.; Chang C.-C.; Chen K.-C.; Yin W.-H.; Wu C.-C.; Chan S.-H.; Wu Y.-W.; Wang K.Y. |
| 臺大學術典藏 |
2020-12-28T06:26:53Z |
Cardiac involvement in malignancies: Case 1. Favorable outcome of a patient with cardiac invasion from non-small-cell lung carcinoma
|
Chang Y.-L.; Shih J.-Y.; Ko P.C.-I.; MIN-SHAN TSAI; Min-Shan Tsai;Ko P.C.-I.;Shih J.-Y.;Chang Y.-L.;Chen S.-C.;Chiang W.-C.;Chen W.-J.; Chen S.-C.; Chiang W.-C.; Chen W.-J. |
| 臺大學術典藏 |
2020-12-24T08:26:53Z |
Cardiac involvement in malignancies: Case 1. Favorable outcome of a patient with cardiac invasion from non-small-cell lung carcinoma
|
Chiang W.-C.; Chen S.-C.; Chang Y.-L.; Shih J.-Y.; PATRICK CHOW-IN KO; Tsai M.-S.; Tsai M.-S.;Patrick Chow-In Ko;Shih J.-Y.;Chang Y.-L.;Chen S.-C.;Chiang W.-C.;Chen W.-J.; Chen W.-J. |
| 臺大學術典藏 |
2020-12-24T07:01:25Z |
Estimated creatinine clearance rate is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non-small-cell lung cancer
|
Yang P.-C.; Yu C.-J.; Shih J.-Y.; Chen K.-Y.; JENQ-WEN HUANG; Lin J.-W.; Chen C.-Y.; Chen C.-Y.;Lin J.-W.;Jenq-Wen Huang;Chen K.-Y.;Shih J.-Y.;Yu C.-J.;Yang P.-C. |
